Table 1.

Characteristics of studies of interferon or pegylated-interferon treatment of chronic HCV-infected hemodialysis patients with long-term HCV RNA outcomes on hemodialysis

Study, Country, YearOverall Sample Size (n)Number with SVR (n)Number with Long-Term HCV RNA Outcomes (n)Treatment DoseaTreatment Duration (mo)bLong-Term Follow-Up, Median (mo)
Studies with long-term HCV RNA outcomes with interferon
    Pol, France, 199519663617
    Raptopoulou-Gigi, Greece, 1995191313368
    Okuda, Japan, 199515816618
    Izopet, France, 199723131236 (n = 5)
12 (n = 7)
28
    Fernandez, Argentina, 1997c14331.5612
    Chan, Hong Kong, 199711333618
    Campistol, Spain, 1999c1911113620
    Huraib, Saudi Arabia, 19991712231210
    Espinosa, Spain, 2001136631227
    Hanrotel, France, 2001124231224
    Kamar, France, 200355211636 (n = 3)
12 (n = 13)
37
    Ozdemir, Turkey, 200420886 (n = 5)
3 (n = 3)
6 (n = 5)
12 (n = 3)
64
    Mousa, Saudi Arabia, 20042011103
RBV (200 TIW)
6 (n = 6)
12 (n = 4)
6
    Buargub, Libya, 2006359431212
Studies with long-term HCV RNA outcomes with pegylated-interferon
    Bruchfeld, Sweden, 2006633135 (α-2a), n = 2
50 (α-2b), n = 1
200–300 daily (RBV)
6 (n = 1)
12 (n = 2)
23
    Amarapurkar, India, 20076331.0/kg (α-2b)612
    Ucmaky, Turkey, 20081299135 (α-2a)1230
    Zoppoli, Italy, 20081022135 (α-2a)1222
    Kose, Turkey, 20092692135 (α-2a)129
    Dzekova, Macedonia, 20091455135 (α-2a)1218
    All hemodialysis366159121Variable6 (n = 60)
12 (n = 61)
18
  • α-2a, pegylated-interferon alpha-2a; α-2b, pegylated-interferon alpha-2b; RBV, ribavirin; TIW, three times weekly.

  • a Doses presented for interferon are in million units, three times weekly, and for pegylated interferon alpha-2a or 2b are in micrograms, once weekly. When studies used more than one treatment dose, the numbers reported are based on the group with long-term data.

  • b Intended treatment duration in months. When studies used different durations, the numbers reported in parentheses are from the group with long-term data. More recent studies selected treatment duration based on HCV genotype with 12 months of treatment for genotypes 1 or 4 and 6 months for genotypes 2 or 3.

  • c Randomized controlled trial comparing treated patients versus untreated controls. Sample size reported is the treatment group only.